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Abstract: The presence of false positive and false negative results in the Array Comparative Genomic
Hybridization (aCGH) design is poorly addressed in literature reports. We took advantage of a
custom aCGH recently carried out to analyze its design performance, the use of several Agilent
aberrations detection algorithms, and the presence of false results. Our study provides a confirmation
that the high density design does not generate more noise than standard designs and, might reach
a good resolution. We noticed a not negligible presence of false negative and false positive results
in the imbalances call performed by the Agilent software. The Aberration Detection Method 2
(ADM-2) algorithm with a threshold of 6 performed quite well, and the array design proved to be
reliable, provided that some additional filters are applied, such as considering only intervals with
average absolute log2ratio above 0.3. We also propose an additional filter that takes into account the
proportion of probes with log2ratio exceeding suggestive values for gain or loss. In addition, the
quality of samples was confirmed to be a crucial parameter. Finally, this work raises the importance
of evaluating the samples profiles by eye and the necessity of validating the imbalances detected.
Keywords: high density custom CGH array; agilent aberration call software; CNV detection filters
1. Introduction
Array-based comparative genomic hybridization (aCGH) has provided a new impulse to
cytogenetic diagnostics and has proved to be a valuable tool in the clinical management of patients
with developmental delays and multiple congenital anomalies [1]. This approach has also allowed the
identification of novel chromosomal syndromes [2,3], helped to define the clinical variability associated
with several genomic disorders [4], and led to the discovery of polymorphic copy number variants
(CNVs) in the human genome [5–7].
Early CGH arrays were composed of large-insert bacterial artificial chromosome (BAC) clones
and later evolved to microarray-based technology oligoarray CGH (aCGH).
There were concerns about procedure variability and interpretation criteria for the clinical
application of early versions of targeted BAC clone array because of the presence of false negative
results [8]. Two studies attempted to estimate the false positive (FPR) and false negative (FNR) rates.
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Wong et al. [9] analyzed six repeated experiments on 95 individuals. Given the very low binomial
probability of detecting by chance the same clone twice within six experiments, they assumed that any
clone detected twice or more in their experiments was a true CNV [9]. In this way, they calculated
a FNR of 45.3% and a FPR of 0.23%. Following a similar method, de Smith et al. [10] calculated an
estimate of FNR of 0.16 [10]. The FPR was instead estimated to be 0.05 for multi-probe calls by using
three self-self hybridizations of the reference sample and comparing the average number of variant
interval calls with that calculated for each sample. However, a few studies validated BAC clone arrays
by examining well ascertained CNVs [11,12].
The more recent development of oligonucleotide aCGH has led to a greater resolution in CNV
identification. Concordance for oligo aCGH with BAC array was shown [13,14], with around 99%
sensitivity and 99% specificity [11,15] and superior performance of oligonucleotide aCGH over BAC
clone aCGH [13,16].
However, all these studies based their confirmatory results on imbalances of standard cytogenetic
size (Mbs). In addition, high probe density might generate more noise in aCGH data. Using two
different Agilent CGH microarrays, it has been shown empirically that subject-to-subject variance
is almost twice as large as array-to-array and dye-to-dye variance, supporting results reliability.
However, the same study showed that the array-to-array variability was more than 10 times larger
than both subject-to-subject and dye-to-dye variance for a custom microarray [17]. This observation
was suggested to be ascribable to the fact that to achieve the highest possible density coverage might
have lead to include less reliable probes.
The use of oligo array, though increasing resolution, has lead to a lower specificity and higher
potential for noise, with need for several adjacent probes to confidently identify CNV regions and
a large amount of data analysis and result interpretation. Each of the necessary steps of data
transformation, normalization and summarization involves algorithm parameters that directly affect
the sensitivity and specificity of the aCGH assay and represents a source of potential Type I and Type II
errors [18]. The analysis can be complicated by the presence of platform and method artifacts including
GC-waves [19,20] and by centralization methods [21].
More recently, the growing use of custom arrays, which are based on libraries of validated
synthetic probes that can interrogate relevant genomic regions, have further enhanced the resolution
capabilities of targeted regions [22–26]. In addition, single nucleotide polymorphism (SNP) arrays
have been exploited to search for CNVs: not feasible for single-exon resolution throughout the
genome, they nonetheless have the advantage to provide genotypes and detect regions of absence
of heterozygosity (AOH) thus also allowing the identification of uniparental isodisomies (UPD)
and genetic identity by descent [27]. However, the amount of data produced by SNP arrays is
computationally challenging and requires a burden of analysis and filters to allow interpretation
of results, and it is not yet well described whether the widely used SNP-array-based CNV calling
methods can provide sufficient concordance with CGH in CNV detection [28]. In addition, SNP array
were shown to not outperform oligonucleotides aCGH in a study that carried out a CNV search by the
Affymetrix 6.0 SNP array on patients with developmental disorders already found negative by oligo
aCGH at higher resolution [29]. Combining SNPs and oligo arrays in a single assay is increasingly
being employed, with the advantage to obtain genotypes and a higher resolution with respect to aCGH
data alone [30]. However, if the final goal is limited to the search of CNVs, oligo aCGH remains the
most cost effective and straightforward method.
Several quality metric variables can be used to evaluate the quality of the oligo array and dataset,
such as probe-to-probe log2ratio noise, signal intensity, background noise channels, signal to noise and
reproducibility. In addition, CNVs are generally claimed when several probes are indicative of CNVs,
although this reduces the array resolution. However, false positive and false negative results are still
an issue.
A few studies regarding preimplantation genetic screening in human assisted reproduction
showed a not infrequent presence of false positive and false negative results from aCGH [31,32].
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In particular, Capalbo A. et al. [31] compared aCGH and qPCR on 120 aneuploid blastocysts, finding
that 18.3% of embryos gave a discordant result for at least one chromosome and that most of these
were due to aCGH false positive results.
A small number of other studies mention the presence of false positive and false negative results
detected, for instance, by the use of different aberration detection methods [24], or the finding of
possible aberration missed at aCGH when reanalyzing the results by Next Generation Sequencing
(NGS) [26]. However, in our opinion, the presence of false and positive results is not addressed enough
in the results reported in the literature.
Abnormal results should be confirmed and various strategies have been described to follow-up
analysis, including repeated aCGH testing, fluorescence in situ hybridization (FISH), microsatellite
analysis, multiplex ligation-dependent probe amplification (MLPA) and, in particular, real-time
quantitative PCR (qPCR). Recently, NGS has also been suggested [26].
Nonetheless, aCGH remains the first-tier testfor CNV detection, due to its genome wide
applicability. Validation on a large number of patient and control samples following aCGH analysis is
not practical, and it is not always reported in large screenings [33,34], or only few interesting candidates
are validated [26].
We took advantage of a custom aCGH, recently carried out on 59 patients affected by Hirschsprung
Disease (HSCR) to search for imbalances in genes and loci candidate for HSCR [35], to analyze its
performance, the use of several aberrations detection algorithms, and the presence of false positive
and false negative results.
2. Results
2.1. Sample Quality and Design Reliability
DLRSs (derivative log ratio spread) and the other metrics of the final 59 samples analyzed for the
search of aberrations are shown in Figure 1. The DLRS, in particular, is a measure of the log ratio noise
for each sample, calculated as the standard deviation (spread) of the log ratio differences between
consecutive probes.
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Figure 1. Quality control metrics: Distribution of the sample quality controls is reported as box plots
and as statistics. In particular, sample metrics are highlighted as excellent, good or poor (evaluate) and
how many samples are in each category is also reported. Solid circles and asterisks in the box plot
graphs represents the outliers: solid circles are cases with values more than 1.5 times the InterQuartile
(IQ) range, asterisks are cases with values more than 3 times the IQ range.
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To assess the reliability of the results, we correlated the log2ratios between replicates as reported
elsewhere [36], finding low correlations (mean r = 0.18 across 37 comparisons), though higher than
among random sample pairs (mean r = 0.07, p = 0.0040) (Table 1). Such a low correlation is not
unexpected since log2ratios not different from zero are supposed to vary randomly. As a matter of fact,
considering only log2ratios with absolute values above 0.3, the mean correlations improved in both
replicated and random sample pairs (mean r = 0.42, p = 1.8 × 10−9 and 0.14, p = 0.0036, respectively),
but at a much higher rate for the replicates (p = 4.8 × 10−5). These results reassure on the design quality
and suggest that the application of a minimum log2ratio values criterion, such as the mean absolute
log2ratio > 0.30 (hereafter referred as MALR > 0.30), is reasonable and advisable. Not surprisingly,
the level of correlation is dependent on the derivative log ratio spread (DLRS): correlations between
replicates and random pairs were significantly different only when at least one sample had DLRS ≤ 0.2
(p = 6.8 × 10−6 on |log2ratio| ≥ 0.3). Correlations were much lower and not significant for the 13 pairs
with both samples with DLRS > 0.2 (r = 0.21 for replicates and r = 0.09 for random pairs).




All Log2ratios Log2ratios > |0.3| p-Value
Mean r Mean r
All samples
replicated 37 0.18 0.42 1.8 × 10−9
random 37 0.07 0.14 0.0036
p-value 0.004 4.8 × 10−5
Only pairs with at least one
excellent quality sample
(DLRS ≤ 0.2)
replicated 24 0.23 * 0.53 § 2.01 × 10−8
random 24 0.09 ** −0.17 §§ 0.0057
p-value 0.0018 6.8 × 10−6
Pairs with no excellent
quality sample (DLRS > 0.2)
replicated 13 0.09 * 0.21 § 0.003
random 13 0.05 ** 0.09 §§ 0.1594
p-value 0.2635 0.1492
* p = 0.0069; ** p = 0.2320; § p = 0.0009; §§ p = 0.2188.
Of note, although we could not find any correlation between the DLRS and the log2ratio values,
besides a faint negative trend, correlations between pairs in which at least one sample had DLRS ≤ 0.2
were significantly higher than correlations between pairs without any sample with DLRS ≤ 0.2, for
replicates but not for random pairs (i.e., r = 0.53 vs. 0.21, p = 0.0009 for replicates and r = 0.17 vs. 0.09,
p = 0.2188 for random pairs on |log2ratio| ≥ 0.3) (Table 1).
Following the method described elsewhere [10], we estimated the FPR for the Aberration Detection
Method 2 (ADM-2) at threshold 6 to be 0.130 for single-probe calls and 0.184 for single-probe
calls, higher than that estimated by de Smith et al. [10]. However, all the aberrations called in
the three self-self test regarded the high density region around RET (10q11.2), confirming that this
sub-centromeric region is problematic, and presented with MALR < 0.3, so that applying such a filter
the FPR virtually dropped to 0. Of note, all the calls on this gene, including those that seemed likely or
possible, were not confirmed at validation.
We also estimated the FNR in a manner similar to that described by Wong et al. and
de Smith et al. [9,10]. In the four replicated experiments, 13 putative variant intervals were observed
twice and then considered true calls, yielding an estimate of FNR of 0.50. We also evaluated three
samples assayed in triplicate, finding an average FNR of 0.213. The FNR found in the four replicates
experiments was slightly higher than that estimated by Wong et al. [9] and definitely higher than
that estimated by de Smith et al. [10], while it was closer to their estimates for the three replicates
experiments. However, we calculated that if Wong et al. [9] had performed four (or three) replicates,
they would have estimated a FNR of 0.3629 and 0.2111, respectively, similar to those obtained by us.
The studies by both de Smith et al. [10] and Wong et al. [9] made use of BAC-based CGH, so that
a direct comparison with our results might be misleading. Nevertheless, a high FNR (above 20%),
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with calls that were missed in one or more replicates, and a very low FPR were confirmed. This latest
estimate is based on a reference DNA with very high quality (DLRS < 0.15) and we cannot exclude
that FPR would have been higher with worse quality samples. Accordingly, few imbalances could not
be validated or confirmed in replicates.
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Figure 2. Sample profiles. An exa ple of four samples selected for excellent quality, good, evaluate
and very bad quality. For each, the profile at chromosome 9 is shown, including a region of probes
scattered across the genome and two high density regions. The upper high density region inside the
blue box in the left panel is zoomed in into the central panel (inside the large blue box) and the specific
region inside the yellow box is further zoomed in into the right panel (inside the large yellow box).
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2.2. High Density Design Performance
Notwithstanding the possibility that high density regions might present low replicability and
display worse profiles than less high density region, when zooming in the regions we did not observe
any higher variability in the profiles between high density probes regions and the rest of the genome
(Figure 2).
Accordingly, we found that the number of calls in the selected regions correlated with the number
of probes analyzed (r = 0.773) as expected, while it did not correlate with either the size or the probe
density of the region selected. These observations were confirmed considering only calls sustained
by at least two probes or considering the number of probes called instead of the number of calls.
When only calls with MALR > 0.3 were considered, no correlation could be detected at all (Figure 3).
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Figure 3. Aberration calls and probes correlations. Correlation between the number of calls detected in
each high density region and the number of probes selected in each region (upper) or the probe density
(number of probes/size) of the selected region (bottom) considering any calls, including: single probe
calls (A); or only multi probes calls with MAAD > 0.3 (B).
Redundancy of probes covering the same target sequence might instead create problems in the
hybridization and thus false results, as we could observe in a preliminary design.
2.3. Comparison between Algorithms and Filters
Applying the ADM-2 algorithm with a threshold of 6, the CG correction and the centralization
algorithms, and excluding the positive control regions, we got 572 aberration calls on autosomal
chromosomes (for a median of seven calls per sample, range 1–34), 393 of which sustained by at least
two consecutive prob s (five median calls per sample, range 1–17). We also repeated the analysis
without the GC correction but no dif erence could b detected in the r sults.
However, at th amples profiles visual inspection, most of the calls seeme o us as false
positives, for t is reason we have also applied two additional filters, MALR > 0.30 and thresholde > 0.33.
Wit the first filter we obtained 75 calls, six of which corresponding to the already known chromosomal
alterations (for these latter we got nine calls, but five were overlapping for the two chromosomal RET
deletions on the two sample used as controls for this region and are not reported in Table 2). Two CNVs
were not found in the best quality sample firstly evaluated but were added to the list because found
in the two additional good quality replicates. These 77 aberrations reduced to 52 considering the
thresholde > 0.33, an empirical threshold based on the number of probes with specific log2ratio ranges
that we have applied to the present data (see the methods) (Table 2).
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CNV Type # Probes











HSCR000 0.148 9:110381888–110401999 gain 9 Y Y Y likely N N Y confirmed yes
HSCR000 0.148 10:43435867–60812533 loss 849 Y Y Y known N N known confirmed known
HSCR000 0.148 10:43572551–43573368 gain 3 N N N unlikely N N not confirmed no
HSCR037 0.120 10:43589687–62786887 loss 544 Y Y Y known N N known known
HSCR005 0.226 7:84217007–84225649 loss 4 Y - - likely Y (freq < 1%) N Y yes
HSCR005 0.226 10:43679892–43680816 loss 5 Y - Y likely N N N no
HSCR005 * 0.226 21:9833187–11096086 loss 4 N - N possible N N unknown
HSCR006 0.276 10:43679612–43680816 loss 6 N - - likely N N N no
HSCR006 0.276 10:43685614–43715348 gain 78 N N - unlikely N N unknown
HSCR006 0.276 19:5822193–5832504 gain 13 Y - - unlikely N N unknown
HSCR009 0.176 10:43691613–43713132 gain 50 N N N unlikely N N unknown
HSCR009 0.176 19:5825458–5831976 gain 9 Y Y Y unlikely N N unknown
HSCR010 * 0.211 15:20848460–22432687 gain 5 Y - - likely Y (freq ≥ 5%) N not excluded yes
HSCR014 0.221 8:32532001–32532545 gain 2 Y - Y unlikely N N unknown
HSCR014 * 0.221 10:29939955–30822470 gain 3 Y - Y possible N N unknown
HSCR014 * 0.221 12:80226392–80589429 gain 2 Y - Y possible N N unknown
HSCR014 0.221 22:22417683–23228483 loss 15 Y Y Y likely Y (freq ≥ 5%) N yes
HSCR016 0.117 5:69288477–70309855 gain 3 Y - - likely Y (freq ≥ 5%) N not excluded yes
HSCR016 0.117 22:25672585–25892401 gain 5 Y - Y likely Y (freq ≥ 5%) Y (3 inds.) not excluded yes
HSCR018 § 0.172 9:109336464–109348467 gain 6 - - - likely N N Y yes




Y confirmed witha different size yes
HSCR033* 0.229 15:21162691–22173977 loss 3 Y Y Y likely Y (freq ≥ 5%) N yes
HSCR036 0.177 22:22781091–23228483 loss 8 Y Y Y likely Y (freq ≥ 5%) N yes
HSCR039 0.217 3:51458492–51665134 loss 62 N N - unlikely N N not confirmed no
HSCR039 0.217 6:148651353–150170473 loss 52 N N - unlikely N N not confirmed no
HSCR039 0.217 9:110130442–110370427 loss 99 N N - unlikely N N not confirmed no
HSCR043 § 0.175 9:109273643–109275694 loss 2 - - - likely N N Y yes
HSCR045 § 0.271 7:84594683–84607065 loss 6 - - - unlikely N N N no
HSCR045 § 0.271 8:32597644–32598929 loss 3 - - - likely N N Y yes
HSCR045 0.271 10:43679612–43680816 loss 6 Y - Y likely N N N no
HSCR045 0.271 19:5819037–18310693 gain 25 Y - - unlikely N N unknown
HSCR058 0.243 22:18661724–18920001 gain 7 Y - Y unlikely Y (freq ≥ 5%) N not evaluable yes
HSCR064 * 0.192 15:20848460–22173977 loss 4 Y Y Y likely Y (freq ≥ 5%) N yes
HSCR126 0.176 19:4205366–18310693 gain 26 N - - unlikely N N unknown
HSCR146 * 0.122 15:58257674–59009890 gain 2 Y Y Y likely N N Y yes
HSCR146 0.122 19:30888070–30891329 gain 2 Y - Y likely N N N no
HSCR160 * 0.200 15:20848460–22173977 gain 4 Y - Y likely Y (freq ≥ 5%) N yes
HSCR162 *,§ 0.184 9:43659247–43659512 loss 2 - - - likely Y (freq ≥ 5%) N confirmed witha different size yes
HSCR181 * 0.150 15:20848460–22432687 loss 5 N - - possible Y (freq ≥ 5%) N not excluded yes
HSCR181 0.150 21:14629063–48080926 gain 245 Y Y Y known N N known confirmed known
HSCR183 0.138 22:22781091–23228483 loss 8 Y Y Y likely Y (freq ≥ 5%) N yes
HSCR195 0.158 9:112078131–112089193 loss 5 Y - - likely N N inconclusive confirmed witha different size yes
HSCR217 0.168 16:82200334–82202467 gain 2 Y - Y likely N N Y yes
HSCR228 § 0.158 22:25672585–25892401 gain 5 - - - likely Y (freq ≥ 5%) Y (3 inds.) not excluded yes
HSCR231* 0.164 15:21162691–22432687 gain 4 Y - Y unlikely Y (freq ≥ 5%) N yes
HSCR312 0.215 3:50161771–50618134 gain 143 N - - unlikely N N unknown
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HSCR312 0.215 4:41748211–41753993 gain 16 N - - unlikely N N unknown
HSCR312 0.215 10:43550696–43621994 gain 196 N - - unlikely N N unknown
HSCR312 0.215 10:43684681–43718450 gain 86 N N N unlikely N N unknown
HSCR312 0.215 14:36983123–36994136 gain 14 Y - - unlikely N N unknown
HSCR312 0.215 19:5821171–5832504 gain 15 N N N unlikely N N unknown
HSCR323 0.253 13:78465278–78484576 gain 30 N - - unlikely N N unknown
HSCR331 0.172 19:5822193–5832928 gain 14 N - - unlikely N N not excluded unknown
HSCR335 * 0.183 15:20848460–22173977 gain 4 Y - - possible Y (freq ≥ 5%) N not excluded yes
HSCR335 0.183 22:18628019–18807881 gain 6 Y - Y unlikely N N not excluded unknown
HSCR335 0.183 22:20345868–20499789 gain 4 Y - Y unlikely Y (freq ≥ 5%) N not excluded yes
HSCR335 0.183 22:21494163–21704972 gain 5 Y - Y unlikely N N not excluded unknown
HSCR349 0.220 3:51452049–51647312 loss 59 N N - unlikely N N unknown
HSCR349 * 0.220 7:63449575–75986814 loss 25 N - - unlikely N N unknown
HSCR349 0.220 10:43573685–43574005 gain 2 Y - Y unlikely N N N no
HSCR374 0.266 10:43473690–43474033 gain 4 Y - Y unlikely N N N no
HSCR380 0.123 22:16054691–18807881 gain 23 Y Y Y known N N known known
HSCR380 0.123 22:20345868–20659606 gain 5 Y Y Y unlikely N N unknown
HSCR380 0.123 22:21494163–21704972 gain 5 Y Y Y unlikely N N unknown
HSCR382 0.235 10:43474436–43483543 loss 29 N - - unlikely N N unknown
HSCR382 0.235 10:43630181–43636329 gain 31 N - - unlikely N N unknown
HSCR382 * 0.235 15:20190548–22173977 gain 5 Y - - possible Y (freq ≥ 5%) N yes
HSCR391 0.173 21:14629063–48080926 gain 245 Y Y Y known N N known confirmed witha different size known
HSCR403 §§ 0.111 4:41746863–41751291 loss 11 N - - likely N N Y yes
HSCR403 *,§§ 0.111 9:43659247–43659512 gain 2 Y - Y likely Y (freq ≥ 5%) N yes
HSCR403 0.111 22:18661724–18807881 gain 5 Y - - possible N N not excluded unknown
HSCR403 0.111 22:21494163–21704972 gain 5 Y - Y unlikely N N confirmed andnot excluded yes
HSCR403 0.111 22:23056562–23228483 loss 3 Y - Y likely Y (freq ≥ 5%) N confirmed witha different size yes
HSCR409 * 0.139 15:20848460–22173977 gain 4 Y Y Y likely Y (freq ≥ 5%) N yes
HSCR412 0.204 22:20345868–21778882 loss 26 N - - unlikely N N not confirmed no
HSCR414 * 0.156 15:20848460–22432687 loss 5 N - - possible Y (freq ≥ 5%) N yes
HSCR415 0.195 9:113025039–113029430 loss 2 Y Y Y likely Y (freq ≥ 5%) Y (1 ind.) ‡ yes
HSCR421 * 0.166 9:43659247–43659512 loss 2 Y Y Y likely Y (freq ≥ 5%) N confirmed yes
HSCR421 0.166 22:25672585–25892401 loss 5 Y Y Y likely Y (freq ≥ 5%) Y (3 inds.) not excluded yes
HSCR426 * 0.111 9:43659247–43659512 loss 2 Y - Y likely Y (freq ≥ 5%) N not confirmedand confirmed yes
HSCR481 * 0.248 5:7656467–8124532 loss 2 Y - Y possible N N not confirmed no
HSCR481 0.248 19:31954093–31966036 loss 5 Y - - likely N N Y not evaluable yes
HSCR481 0.248 21:14629063–48080926 gain 245 Y Y Y known N N known confirmed known
† True (yes) = if either already reported on DGV, validated with different methods or confirmed on at least one replicate; (no) if not validated and/or not confirmed on replicate(s);
known = selected controls or known chromosomal rearrangements; unknown = not possible to discriminate between true yes or no; * probes not located in the selected high density
regions; § aberration not detected by the software call, but identified by visual inspection; Y = percentage of probes with absolute high log2ratio (≥0.5 for gains and ≤−0.8 for loss)
above 33.3%; N = percentage ≤ 33.3%, - = not called by the algorithm; ‡ deletion reported as CNV with pathogenicity unknown, reported in an individual with aganglionic megacolon
(another name for HSCR), intellectual disability and short stature; §§ aberrations assumed as detected because identified in two additional replicates.
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Forty-two calls were detected with the same two filters applying the Fuzzy-zero algorithm,
while 22 aberrations were called applying the ADM-2 algorithm with a more stringent threshold of 8.
The visual inspection of the sample profiles allowed us to add six calls to the list of aberrations,
for a total of 83 aberrations in 61 different chromosomal locations (including controls) in 44 samples.
Excluding aberrations previously reported on DGV and controls, 51 aberrations were detected
in 25 patients, two of which repeated in three patients each. The variants called reduced to
25 aberrations in 17 patients when applying the thresholde > 0.33, to 15 aberrations in nine patients
applying the more stringent threshold of 8 and to 24 aberrations in 16 patients applying the fuzzy-zero
algorithm (Table 2).
For 15 of the novel aberrations we had at least one replicate sample available, although for two
samples the replicate was of low quality (DLRS ≥ 0.3). While one replicate was inconclusive because of
a too noisy profile (a low quality replicate), six were definitely not replicated, four were likely although
not called by the software and four were clearly replicated, although two showed a different size.
2.4. Software Algorithms Calls and Visual Inspection
The visual evaluation of the log2ratio sample profiles allowed the identification of additional
putative aberrations, not detected by the software, suggesting the substantial chance of false negative
results. Of the 44 CNVs classified as likely or possible based on visual inspection and further verified,
39 resulted to be true (confirmed at the validation, detected also on a second replicate or reported on
DGV and thus assumed as true, in addition to the six known aberrations all very well visible). Among
those classified as unlikely, instead, only four could be claimed as true while eight were excluded at the
validation (p = 0.0004), suggesting that the visual inspection of the sample profile is crucial, and even
more reliable than the use of algorithms for the variant calls (Table 3).








Unlikely or Called vs. Not
Called by the Software *
p-Values
Thresholde ≥
0.33 vs. below *
Likely/possible 39 5 4 48
0.0003 †Unlikely 4 8 23 35
ADM-2_th6 ≥ 0.333 35 6 12 53
1.0000 0.0033 ††ADM-2_th6 < 0.333 3 6 15 24
NO ADM-2_th6
(visual only) * 5 1 0 6
ADM-2_th8 ≥ 0.333 18 0 3 21
0.5346 0.0001 ††ADM-2_th8 < 0.333 0 4 5 9
NO ADM-2_th8 25 9 19 53
Fuzzy ≥ 0.333 28 6 8 42
0.5230 0.2000Fuzzy < 0.333 0 1 4 5
NO Fuzzy 15 6 15 36
Total 43 13 27 83
True calls include controls, aberrations reported on DGV, aberrations confirmed in at least a replicate and aberrations
confirmed at validation. Not confirmed calls include aberrations not confirmed at validation and not found in the
available replicate. Unknown includes calls not validated and not reported on DGV, for which a replicate sample
was not available and that have not been evaluated in the statistical test. * p-value for true vs. not confirmed calls;
† likely/possible have a significantly higher chance of being true than those unlikely; †† the thresholde ≥ 0.33 filter
has a better chance to discriminate between true and false calls, significant for the ADM-2 detection algorithm.
To note, by comparing the visual inspection results with the software calls under various scenario
(a more stringent threshold of 8 for the ADM-2 algorithm, the application of the Fuzzy zero algorithm
and thresholde > 0.33 filters), under the application of the MALR > 0.3 with at least two probes filter,
the ADM-2 algorithm with threshold 6 together with the application of the thresholde > 0.33 filters
resulted to be the most comparable with the visual inspection, and the thresholde > 0.33 in general
Int. J. Mol. Sci. 2017, 18, 609 10 of 17
resulted to be a good discriminatory filter (Table 3). Both the ADM-2 algorithm with a threshold of 8
and the Fuzzy zero algorithm missed too many true calls (25 and 15, respectively).
3. Discussion
The search for CNVs in genes and loci candidate for HSCR in a panel of individuals affected by
the disease has provided the opportunity to investigate in more detail the quality of our custom aCGH
design and to address some general remarks. First of all, we could confirm that the use of a high density
design does not seem to increase the error in variants detection, neither lead to worse sample profiles,
thus confirming the validity of this strategy of searching for small imbalances, otherwise undetectable.
The size of the imbalances that can be detected depends upon the density of probes targeting
the regions of interest and the criteria set for software-generated calls (i.e., minimum two probes as
applied here). Redundancy of probes covering the same target sequence might create problems in the
hybridization and thus false results. In addition, not all probes perform equally well. However, the
selection of probes and the density in the coverage of the array, which in our design was up to one
probe every 250 nt (for RET), might greatly increase the CNV search resolution, provided that there
is no probe overlap. We could detect a few imbalances that are less than 5 kb that were successfully
confirmed by other techniques.
Not surprisingly, the quality of samples is confirmed to be a crucial step. There is no correlation
between the number of calls detected by the algorithm software and the DLRS of the samples, as it
is expected since the algorithm already took into account the sample quality. However, the log2ratio
correlation between replicates was greatly improved when DLRS were excellent (≤0.2). To note, among
calls with MALR > 0.3, those detected in samples with excellent DLRS were classified as “likely” or
“possible” more frequently than those detected in sample with worse DLRS. “Likely” and “possible”
variants could be grouped, although “likely” variants seemed to be true variants more often than
“possible” variants (30 vs. 4 compared to 4 vs. 1).
Above all, our study highlighted the importance of the visual inspection by an expert eye.
The human eye can take into account several factors such as the general profile of the sample, the
specific region profile, and the single log2ratio values involved in the putative aberration qualitatively
better than any algorithm. Of course, in the case of a large screening, the use of algorithms becomes
a pivotal tool. In this case, we noticed that the ADM-2 algorithm with the threshold of 6 suggested
by the Agilent company performed quite well, provided that a minimum absolute log2ratio for the
region is taken into account, such as a MALR > 0.30, as already applied in several studies. In addition,
we suggest that also the number of probes concordant should be considered to call the imbalance.
For instance, we applied an empirical filter that evaluated if at least one thirds of the probes were
above (for gain) or below (for loss) a certain cutoff value, here chosen to be +0.5 and −0.8, finding
that the chance to discriminate between true and false calls was greatly improved, especially with the
ADM-2 detection algorithm.
A more stringent threshold value for the ADM-2 algorithm did not seem to improve the detection
of true imbalances, while, conversely, was at risk of missing the call of several possibly true variants.
The same can be said for the Fuzzy Zero algorithm. It is useful for large regions that however are easily
detectable as false positive also by the visual inspection of the samples profile.
Very evident large calls, clearly visible at visual inspection and with a neat discrimination above
the baseline, were identified with a high level of confidence. They were also easily replied in replicates,
including very low quality replicates. This happened for instance for the loss and gain CNVs we
included as controls and for two Down syndrome samples. Similarly, the first studies that investigated
the reliability of aCGH were mostly based on this sort of gold standard and achieved a complete or
almost complete concordance. It remains to explain why other smaller calls seem to be less evident.
One possibility is that smaller calls rely on a small number of probes and are therefore more dependent
on local probes quality. In addition, problematic regions (such as those closed to centromere) had
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variability: the RET region, known to be difficulty at amplification and screening, was the one to show
most false results. In addition, mosaicism cannot be excluded to explain this observation.
It has been suggested that an additional source of variability is given by bench bias [17]. We did
not presently investigate such a matter, but from our observation we cannot exclude that correlation
and concordance in aberrations calls is dependent on the array and time at which the experiment has
been carried out.
Finally, it has also been shown that the fluorescent dyes commonly used in array CGH,
fundamentally the red dyes, are sensitive to ozone, and that ozone has a very strong effect on array
data especially during the post-hybridization step [37]. We did not specifically address the possibility
of false results in this context; however, the arrays were washed and dried under laminar flow hoods in
a semi-darkness environment to reduce ozone exposure. Accordingly, we did not observe a difference
in gain/loss ratio among the different groups of CNVs (likely, possible, unlikely, true or not true), with
the exception of the variants defined as unlikely, basically due to CNVs bigger than 5 kb. The four
unlikely true variants (thus possible false negative) were all gains (red dyes predominant) bigger
than 5 kb, while among the eight not true variants (possible false positive), the three variants smaller
than 5 kb were all gains, and the five variants bigger than 5 kb were all losses. Thus, we cannot exclude
that ozone has affected our data, but if this is the case it seems to affect less the smaller aberrations.
In accordance with the impression we got by visual inspection, we have estimated high false
positive and false negative rates for the software calls, though these figures need to be taken cautiously.
Indeed, we had some concerns given to the fact that few variants detected were then excluded by
alternative methods (such as three unlikely and one likely losses and gains excluded by qPCR) and,
on the other hand, we were able to detect variants missed by the software and that were successively
confirmed to be true (such as three likely losses and gains confirmed by qPCR). Similarly, a deletion
found in a sample for which we had two additional replicates, was also detected on the bad quality
replicate but not on the good one. In addition, we found two true aberrations in a sample that was in
triplicate that were not detected in the best quality replicate and would have thus gone undetected.
Therefore, our observations strengthen the need to validate the results by means of other
techniques, among which qPCR is particularly recommended. A priori use of a combined oligo
aCGH and SNP array might have avoided some false results, too. Supposed deletions could have been
excluded based on heterozygote genotypes in the same region, for instance. However, the non-uniform
distribution of informative SNPs throughout the genome might nullify such advantage in specific
regions, especially in the case of small CNVs.
Most of the observations reported here come from visual classification, thus lacking of a proved
gold standard. Nevertheless, our study provides a confirmation that the high density design of
aCGH does not generate more noise than lower density designs and, in addition, does reach a better
resolution, with the finding of validated imbalances smaller than 5 kb. In conclusion, our design
proved to be reliable, provided that some filters are applied such as MALR ≥ 0.3. We also propose an
additional filter, treshholde > 0.33, which takes into account the proportion of probes with log2ratios
exceeding suggestive values for gain or loss. In any case, besides the use of additional filters, we would
like to stress the importance of paying a great attention to the observation of the samples profiles and
the necessity of validating the imbalances detected.
4. Materials and Methods
4.1. Microarray Design
The sample was constituted by 59 Italian sporadic HSCR patients, six of whom carrying known
chromosomal aberrations at the karyotype level: three chromosome 21 trisomies, an invdup(22)(q11)
and two interstitial deletions in 10q11.21. The clinical features, selection and processing of the samples
are described elsewhere [35].
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We have designed a high-density custom array (8X15K SurePrint G3 Human Kit, Agilent
Technologies, Santa Clara, CA, USA) through the Agilent eArray web portal. Genomic DNA (test)
and sex-matched controls (Promega, Madison, WI, USA) were labelled and hybridized following
the protocols provided by the manufacturers. Spot intensities were processed by Agilent Feature
Extraction software and the text file outputs were imported into Agilent Genomic Workbench v. 5.0.14
software (Agilent Technologies, Santa Clara, CA, USA) distributed by the vendor.
The microarray consisted of 8333 probes at a high density, selected to cover 20 HSCR candidate
genes as described elsewhere, and 3130 probes scattered along the genome, with a probe density
of around 1 probe every 900 kb, that constituted the backbone together with 1262 normalization
probes (13 of which located in the selected regions), 301 probes replicated five times (1505 probes),
and 1482 control probes provided by Agilent (Table 4).
Table 4. Regions mapped on the aCGH and probe density.









9q31 9q31 1824 2501
9p24.1 9p24.1 142 3521
PHOX2B 4p13 49 508
NRG1 8p12 473 501
SEMA3A/SEMA3D 7q21.11 468 2506
rs12707682 40 500
6q25.1 6q25.1 714 3501
21q22 21q22 202 48,297
3p21 3p21 1141 3503
19q12 19q12 1085 3502
NRTN 19p13.3 18 806
16q23.3 16q23.3 714 3501
NKX2-1 14q13 17 812
SOX10 22q13 27 823
22q11.2 22q11.2 162 49,383
ECE1 1p36.1 103 806
ZEB2 2q22.3 165 923
EDNRB 13q22 112 804
GDNF 5p13.1-p12 42 810
EDN3 20q13.2-q13.3 44 808
Genome 3149 3130 971,074





* Twenty-two probes selected among the high density panel were also included in the normalization set or in the
replicates set and are not reported among the # of unique probes selected, but considered for the average coverage.
Nineteen probes selected in the rest of the genome had already been selected for the high density regions (10) or
already part of the normalization set (9).
Gene and locus positions are based on the Human Genome GRCh37 (hg19) assembly of UCSC
genome browser [38].
4.2. Data Analysis and Structural Variant Detection
To investigate genomic imbalances, we applied the ADM-2 algorithm. A threshold of 6 was set,
as recommended by Agilent, and a more stringent threshold of 8 has also been tried.
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We applied the centralization algorithm and the GC correction algorithm, and we repeated the
aberration detection call both applying and not applying the Fuzzy Zero algorithm.
Finally, we have considered as aberrant only those regions with a minimum of 2 probes and
with minimum absolute average log2ratio for region >0.3. In addition, we evaluated the effect
of an additional criteria, the thresholde > 0.33, namely that at least one third of probes in the
putative imbalanced interval (at least 2 probes in the case of aberrations based on 3 probes) must
present log2ratio above 0.5 or below −0.8 for gains and loss respectively (based on log2(3/2) = 0.58,
log2(1/2) = −1).
We also evaluated the samples profiles by visual inspection, reviewed by a second well-trained
operator. Loci with nearby gain or loss intervals and an intervening region of more than 2 probes were
considered two separate CNVs, as well as those differing for 2 probes presenting inconsistent log2ratio
(opposite direction, that is log2ratio < −0.3 for gain and >0.3 for deletions).
4.3. Statistical Analysis
The Agilent Feature Extraction (FE) processes the data, calculates signal log2ratios, estimates
errors, and provides basic QC metrics. In particular, we have evaluated: (i) the DLRSpread (derivative
log2ratio spread), which is a measure of the log2ratio noise for each sample; (ii) the BGNoise
(background noise), which is a measure of the background fluorescence for each channel (Red and
Green); (iii) signal intensity; (iv) signal to noise; and (v) the reproducibility for each channel. Measures
were considered as excellent, good or to be evaluated, based on Agilent’s guideline (Figure 1).
Newly extracted or purified DNA was run on an additional array for 10 samples with bad profiles,
which are those with DRLS ≥ 0.3, and for 16 samples arbitrarily selected. Moreover, four samples
were replicated three times (two of which had the third replicate of bad quality), and one sample was
replicated four times. When more replicates were available, the variants search was performed in the
sample with the lowest DRLS, or, in case of very similar DRLS among replicates, in the one with an
overall better quality. In any case, aberrations detected were evaluated also in the replicated samples,
when available.
The FPR was determined comparing the average number of variant calls in self-self tests with
the average number of variant calls for each sample, using three self-self hybridizations of a reference
sample, as described by de Smith et al. [10]. We estimated the FNR using replicated experiments
as described by Wong et al. and de Smith et al. [9,10] and adjusted their estimates based on BAC
array by changing number of clones with number of probes. While they based their estimate on 6
and 4 replicates, respectively, we used both four and three replicates. Of note, if Wong et al. [9] had
performed 4 replicates only, some calls detected more than once would have been lost (virtually present
in one of the two additional replicates no more present). For this reason, we calculated by permutation
the expected number of calls replicated more than twice by Wong et al. [9] in the case of four (or three)
replicates, assuming a random distribution on the replicates experiments. We considered aberrant
intervals revealed in different experiment as identical if the overlap among probes was ≥0.90.
We also calculated the correlation between replicates and between random sample pairs selected
to have similar DLRS (<0.2, ≥0.2 and <0.3 or ≥0.3). We repeated the analysis for both all log2ratios and
log2ratio exceeding the threshold of absolute 0.3 (considering that those with log2ratio not different
from 0 are not expected to correlate at all) and among all the replicated samples and among only those
with DRLS below the two cutoffs of 0.3 and 0.2. Moreover, we investigated whether the number of
aberrations called by the software correlated with the number of probes called, the size, or the probe
density, excluding from the analysis the aberrations used as controls and considering the aberrations
that overlapped the high density probes regions and the genome as belonging to the high density
group. We assumed the aberration size to be the mean between the inner and the outer probes called.
Finally, we tried to investigate whether there was an association between the calls obtained with
the software under different criteria and the visual inspection results.
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4.4. Detected Variants Classification and Validation
The visual inspection of the aCGHsample profiles has allowed us to classify the aberrations
detected as known (the controls), likely, possible but not convincing (possible), or unlikely (Table 2).
Aberrations were compared with CNVs observed in the normal population and reported in the
Database of Genomic Variants (DGV) [39] and with the CNVs reported in the DECIPHER database
of phenotypes, v8.7 released [40]. The comparison between different platforms and techniques is
tricky, exact boundaries of the aberrations detected by arrays are not known but only assumed to be
between the last “normal” probe (outer) and the first “aberrant” probe (inner) and depend on the
average coverage. However, we considered aberrations as consistent with those already reported in the
databases if they showed an overlap ≥80%, did not differ for more than two probes with compatible
log2ratios (that is ≥|0.3|), and were of the same kind (gain or loss). The frequency of the CNV or the
number of individuals in the database in which the variant is reported was not a selection criterion but
is reported.
We arbitrarily selected the most promising regions (those classified as likely and not reported on
the DGV database) and those more interesting for us (i.e., on the RET gene) for validation with other
molecular biology techniques, and parental check, as described elsewhere [35] and reported in Table 2.
We considered as true calls those detected in the controls (already assessed with other techniques
or trisomy 21 in patients also affected by Down syndrome), the aberrations confirmed at the validation,
the calls detected also on a second replicate and CNVs reported on DGV.
5. Conclusions
Our study provides a confirmation that the high density design of aCGH does not generate
more noise than lower density designs and, in addition, does reach a better resolution. However,
false positive and false negative results are not trivial. For this reason, we suggest that some filters
are applied such as the MALR ≥ 0.3 and the treshholde > 0.33, this latter taking into account the
proportion of probes with log2ratios exceeding suggestive values for gain or loss. We have also shown
the importance of visual inspection of results and the necessity of validating the imbalances detected.
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